NOUSCOM
Nouscom are a well established team that has worked together for many years in previous successful enterprises, including IRBM/Merck and Okairos, and are veterans in the field of oncolytic and genetic vaccines. The company is headquartered in Basel, Switzerland and has operations in Rome, Italy. The NousCom team is lead by experienced enterpreneurs that worked together for many years in previous successful enterprises, such as Okairos, under the leadership of Prof. Riccardo Cortese, who conceived the ideas behind those companies.
NOUSCOM
Social Links:
Industry:
Biotechnology Genetics Health Care Therapeutics
Founded:
2015-01-01
Address:
Basel, Basel-Stadt, Switzerland
Country:
Switzerland
Website Url:
http://www.nouscom.com
Total Employee:
11+
Status:
Active
Contact:
+41612011831
Email Addresses:
[email protected]
Total Funding:
54 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics Google Tag Manager WordPress Google Universal Analytics Font Awesome Global Site Tag Mobile Non Scaleable Content
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
LSP BioVentures
LSP BioVentures investment in Series B - Nouscom
5AM Ventures
5AM Ventures investment in Series B - Nouscom
Versant Ventures
Versant Ventures investment in Series B - Nouscom
Abingworth
Abingworth investment in Series B - Nouscom
Life Sciences Partners
Life Sciences Partners investment in Series A - Nouscom
Versant Ventures
Versant Ventures investment in Series A - Nouscom
Key Employee Changes
Official Site Inspections
http://www.nouscom.com
- Host name: 77.209.214.35.bc.googleusercontent.com
- IP address: 35.214.209.77
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Nouscom"
Nouscom • Re-defining innovation
Nouscom is a next-generation immunotherapy company developing engineered viral vectored vaccines for treatment of cancer. The company has offices, research and manufacturing …See details»
Nouscom • History & Team
Nouscom’s leadership and founding team are successful entrepreneurs, who have previously developed innovative candidate vaccines for a range of infectious diseases that include: Malaria (Ewer et al, 2013), Ebola (Stanley et al, 2014; …See details»
Cancer Genetic Vaccines and Armored Oncolytic …
We combine the use of viral vectors that have been engineered and optimized to express artificial genes encoding high-dimensional strings of human neoantigens, with state-of-the art bioinformatics for cancer neoantigen prediction.See details»
Nouscom - Crunchbase Company Profile & Funding
Nouscom is a developer of an immunotherapy platform that aims to create modified viral vector vaccines for cancer treatment. The company's platform makes use of a portfolio of engineered viral vectors that have been optimized …See details»
Nouscom - LinkedIn
Nouscom is a private clinical stage immuno-oncology company developing off-the-shelf and personalized cancer immunotherapies using proprietary viral vectors with demonstrated high...See details»
Nouscom - Org Chart, Teams, Culture & Jobs - The Org
View Nouscom's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
Nouscom AG – Swiss Biotech
Nouscom is a privately held oncology company developing next-generation immunotherapies. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines …See details»
Nouscom Company Profile 2024: Valuation, Funding
Nouscom General Information Description Developer of an immunotherapy platform designed to develop engineered viral vector vaccines for the treatment of cancer.See details»
Nouscom announces first patient dosed in a Phase 1b Trial with …
Aug 24, 2021 · Nouscom is a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines. Nouscom's proprietary technology platform …See details»
Nouscom Company Profile - Office Locations, Competitors ... - Craft
See insights on Nouscom including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Nouscom • Get involved in our pivotal achievements
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in …See details»
Nouscom raises EUR 67.5 million in series C financing round
Nov 14, 2023 · Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, today announced the …See details»
Nouscom: Patient enrollment of study for metastatic colorectal …
Nov 19, 2024 · Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized neoantigen cancer immunotherapies, announces the completion of patient …See details»
Nouscom announces initial results from Phase 1 trial for NOUS …
BASEL, Switzerland, Sept. 16, 2021 /PRNewswire/ -- Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, today …See details»
Nouscom • Press releases, meetings, and publications
May 8, 2024 · Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked …See details»
Nouscom | VentureRadar
Nouscom is a next-generation immunotherapy company developing genetic neoantigen vaccines and oncolytic viruses for prevention and treatment of cancer. Nouscom’s differentiated and …See details»
Nouscom Aiming to Treat and Prevent Cancers With Neoantigen …
Nov 29, 2023 · NEW YORK – A recently closed $72 million financing round will bolster Swiss biotech Nouscom's efforts to test the efficacy of its two lead cancer vaccines not only in …See details»
Press Releases Archivi - Nouscom
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in …See details»
Nouscom Closes $72M Series C Funding Round - Precision …
Nov 14, 2023 · The financing will specifically allow Nouscom to complete a Phase Ib study evaluating NOUS-PEV plus an immune checkpoint inhibitor in advanced melanoma and to test …See details»
NOUS-209: an article on Cancer Research • Nouscom
Jul 22, 2020 · Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today the publication of new research describing the …See details»